Phase I dose escalation of the oral histone deacetylase inhibitor (HDACi) resminostat in combination with FOLFIRI in colorectal cancer (CRC) patients: The SHORE trial.
Henning Schulze-Bergkamen
No relevant relationships to disclose
Dirk Jaeger
No relevant relationships to disclose
Hans-Georg Kopp
No relevant relationships to disclose
Frank Mayer
No relevant relationships to disclose
Michael Bitzer
Honoraria - 4SC AG
Anna Mais
Employment or Leadership Position - 4SC AG
Karin Resemann
Employment or Leadership Position - 4SC AG
Bernhard Hauns
Employment or Leadership Position - 4SC AG
Julia Asche
Employment or Leadership Position - 4SC AG
Stefan W. Henning
Employment or Leadership Position - 4SC AG
Stock Ownership - 4SC AG
Bernd Hentsch
Employment or Leadership Position - 4SC AG
Stock Ownership - 4SC AG